

Cost-Effectiveness of Universal Screening for CHB Infection in Adults

Mehlika Toy, PhD

Stanford School of Medicine

Department of Surgery, Asian Liver Center

HepB Free didactic session June 15, 2021



Mehlika Toy, PhD

- Instructor at Stanford University School of Medicine
- Epidemiologist and Medical Decision Scientist
- Research using mathematical tools and techniques to analyze health policy problems

Cost-Effectiveness Analysis

- CEA is a method to evaluate the outcomes and costs of interventions designed to improve health
- Help decision maker determine how to allocate resources
- Who is the target audience for the study?

Influence an opinion on a subject or add the weight of information on an intervention

Practice guidelines that may be influenced by a CEA, but eventually physicians and patients who make the decision

Health Effect Measure

Health Effectiveness is expressed in terms of unit of output

- **# Cancer cases detected, infections averted...**
- **Life Years Gained (LYG)**
Gains in longevity without quality of life adjustment
- **Disability Adjusted Life Years (DALYs)**
Not generally used in CEA, less developed country context, minimize DALY's
- **Quality Adjusted Life Years (QALY's)**
Advantage of QALY: Incorporating changes in survival and morbidity in a single measure

QALY is a measure of the length and quality of life gained from an intervention/ treatment– 1 QALY is one year spent in perfect health

Incremental Cost-Effectiveness Ratio

An ICER is calculated:

Incremental Cost

(difference in cost between the new intervention and comparator)

Incremental QALY

(difference in QALY's between new intervention and comparator)

WHO Definition of Cost-Effectiveness

Intervention/treatment is considered Cost-Effective:

Cost is less than 3 x GDP per capita for 1 QALY

- GDP per capita in US in 2019= US\$65,297

In the US, < 195,891/QALY

Cost-saving: if a (new) intervention costs less and gains more QALYs vs. comparator (status quo or current practice)

Cost-Effectiveness of One-Time Universal Screening for Chronic Hepatitis B Infection in Adults in the United States

MEHLIKA TOY, DAVID HUTTON, AARON HARRIS, NOELE NELSON,
JOSHUA SALOMON, SAMUEL SO

Clinical Infectious Diseases 2021 In Press

In partnership with CDC, Epidemiologic and Economic Modeling Agreement

Background

- NHANES 2011-2016 report: 840,000-862,000 CHB adults
- 18-34: 0.30%
35-49: 0.37%
50-64: 0.41%
65+: 0.35%
- NHANES: 33% of the US population are unaware of their CHB infection
- Patient related and healthcare provider (or healthcare system) related barriers account for **low screening** and **diagnosis rates**
- CDC, USPSTF, and the AASLD recommend universal HBsAg screening of pregnant women and risk-based testing of non-pregnant


Aim

- Assess the economic and public health impact of one-time universal screening of the general adult population for CHB in the United States
- Comparing current practice to current practice + one time testing
- Outcomes: Lifetime costs, QALYs, and clinical endpoints

Methods

- Using a Markov model: simulated cohorts' progression through series of health states
- According to NHANES data: HBsAg prevalence among adults >18 years is 0.36%. We multiplied 0.36% by 67% (unaware of their infection) to obtain an estimated prevalence of 0.24% undiagnosed CHB
- Disease progression estimate rates for the model were derived from recent cohort studies and meta-analysis from North America for HBV mono-infected patients
- Two scenarios were considered: current practice vs. current practice plus one-time universal hepatitis B screening
- 33% are currently diagnosed, 36% are linked to care, and 18% of those diagnosed are receiving treatment

Markov Schematic



All states can lead to death (not shown). Highlighted are the initial starting states

Key Input Variables

Variable	Base Case	Range	References
Age/birth cohort	≥18 yrs	18-69 yrs	
HBsAg prevalence in adult US population	0.36%	0.29-0.46%	Patel et al. 2019 (6)
Male to female ratio of positive HBsAg population	58:42		Patel et al. 2019 (6)
Percent not aware of their infection	67%		Patel et al. 2019 (6)
Estimated prevalence of undiagnosed adult US population who are HBsAg positive	0.24%		
Percent adults diagnosed with CHB and linked to care and received antiviral treatment	18%	17-19%	Harris et al. 2020 (7)
Percent adults with cirrhosis diagnosed with CHB who are linked to care and receive antiviral treatment	100%		Assumption
Percent of adults who are eligible for treatment	30%	26-30%	(54-57)
Screening Costs (U.S. dollars) \$			
Cost of hepatitis B serologic tests			
Hepatitis B surface antigen (HBsAg)	\$10.33		Medicare reimbursement
Hepatitis B core antibody (anti-HBc)	\$10.74		Medicare reimbursement
Hepatitis B surface antibody (anti-HBs)	\$12.05		Medicare reimbursement
All 3 hepatitis B tests	\$28.27		Medicare reimbursement
Linkage to Care and Treatment Costs			
Antiviral drug costs per year*	\$502	\$326-\$16,464†	Redbook (Jan 22, 2021) (35)
Initial Baseline Tests (HBeAg, CBC, LFT, HBV DNA)	\$86.74	\$43.23-\$129.71	Medicare reimbursement
Total annual monitoring costs‡	\$369	\$185-\$554	Medicare reimbursement
Clinic visit x 2	\$74 x 2	\$37-\$111	Medicare reimbursement
Ultrasound x 1 (50% none, 50% x 2)	\$125 x 1	\$62-\$187	Medicare reimbursement
AFP x 2 (50% none, 50% x 2)	\$23 x 2	\$12-\$35	Medicare reimbursement
ALT x 2	\$7 x 2	\$4-\$11	Medicare reimbursement
HBV DNA x 1	\$59 x 1	\$29-\$88	Medicare reimbursement
Annual Disease Management Costs**			
Chronic Hepatitis B	\$1,695	\$176-\$6808	Liu et al. 2012 (36)
Cirrhosis	\$5,045	\$176-\$6181	Liu et al. 2012 (36)

Assumptions


- Assuming 60% on generic TDF and 40% on generic ETV
- Adjusted to 2020 USD using the 2020 Medical Consumer Price Index (CPI)
- Annual monitoring: total cost including bi-annual clinic visits and blood tests for ALT and annual HBV DNA level plus assuming 50% would receive additional HCC surveillance consisting of bi-annual liver ultrasound and AFP blood tests as recommended by AASLD guidelines

Results

Clinical outcome and cost-effectiveness of one-time universal HBsAg screening for CHB compared with current practice for a population of 100,000 persons age 18-69 years

	Cirrhosis	Decomp. Cirrhosis	HCC	Transplants	HBV Deaths	Cost*	QALYs	ICER
Current Practice (CP)	24.9	7.6	23.9	8.0	38.0	8,747,703	2,062,384	-
CP + One-time Universal Screening	17.5	4.3	18.4	6.1	27.7	8,484,846	2,062,521	-
Difference	-7.4	-3.3	-5.5	-1.9	-10.3	-262,857	+137	Cost-saving

Sensitivity Analysis on Annual Antiviral Treatment Drug Costs on CE of CHB Screening



Willingness to pay or ICER threshold of \$50,000/QALY is considered cost-effective

Incremental cost-effectiveness ratio for one-time universal hepatitis B screening compared to current practice, by various undiagnosed CHB prevalence points and testing costs

Undiagnosed CHB Prevalence	Base Case ICER (HBsAg test at \$10.33)	Cost-Saving (Testing costs threshold)	Cost-Effective at \$50,000/QALY (Testing costs threshold)
0.01%	\$ 171,971	\$ 0.54	\$ 3.39
0.02%	\$ 81,243	\$ 1.08	\$ 6.77
0.03%	\$ 51,001	\$ 1.62	\$ 10.16
0.04%	\$ 35,879	\$ 2.16	\$ 13.55
0.05%	\$ 26,807	\$ 2.70	\$ 16.93
0.10%	\$ 8,661	\$ 5.40	\$ 33.86
0.15%	\$ 2,613	\$ 8.10	\$ 50.80
0.20%	Cost-Saving	\$ 10.80	\$ 67.73
0.25%	Cost-Saving	\$ 13.50	\$ 84.66
0.30%	Cost-Saving	\$ 16.20	\$ 101.59
0.40%	Cost-Saving	\$ 21.60	\$ 135.45
0.50%	Cost-Saving	\$ 27.00	\$ 169.32

Base cost of the HBsAg screening test is \$10.33

Conclusion

- A one-time universal screening of the US population ages 18-69 years for CHB is cost-saving and would result in better health outcomes with reduction in cases of cirrhosis, decompensated cirrhosis, HCC, liver transplantations, and HBV-related deaths.
- A national recommendation for universal CHB screening beyond pregnant women will greatly simplify the screening process and can be readily included in the electronic medical record system to offer all adults a one-time hepatitis B test.

Thank you!